Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Perlara and Rambam Medical Center enter APOL1 kidney disease partnership

Dec. 28, 2018

First patient dosed in pivotal phase III PROTECT study of sparsentan

Dec. 28, 2018

Antiviral response damages kidney in bacterial sepsis

Dec. 14, 2018

New phase IIb trial investigates efficacy of male contraceptive gel

Nov. 29, 2018

Dimerix begins dosing in phase II trials of DMX-200 for kidney disease

Nov. 23, 2018

Nash Pharmaceuticals reports data on NP-135 in mouse model of kidney fibrosis

Nov. 20, 2018

Calliditas begins phase III study of Nefecon in IgA nephropathy

Nov. 14, 2018

Swedish Medical Products Agency allows initiation of phase I trial of ROSgard

Nov. 13, 2018

Mutations in DKGE cause C3 glomerulopathy

Nov. 12, 2018

Purinergic receptor mutations cause congenital neurogenic bladder

Nov. 12, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...